Glycan Analysis Market by Company Size, Analytical Techniques and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030
The glycan analysis market is expected to reach USD 456 million in 2021 and anticipated to grow at a CAGR of 20.8% during the forecast period 2021-2030.
Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as a swiftly expanding class of pharmacologically active compounds. Currently, over 67% of biologics and 80% of FDA-approved biosimilars incorporate some form of glycosylation. Notably, the pipeline for these interventions is experiencing substantial growth at a Compound Annual Growth Rate (CAGR) exceeding 20%. It's crucial to underscore that in higher eukaryotes like humans, DNA glycosylation of specific biomolecules holds not only functional significance but also provides beneficial pharmacological properties, impacting efficacy, solubility, stability, and antigen binding. Additionally, glycans serve as promising biomarkers aiding in disease prognosis, diagnosis, and predicting treatment efficacy. Various abnormal glycan molecules associated with tumors (e.g., Tn, sialyl-T, sialyl-Tn) and virulent glycoproteins on pathogenic viral surfaces (like the glycan shield linked to the SARS-CoV-2 spike glycoprotein) are presently being investigated as potential therapeutic targets.
However, the complex nature of glycan analysis poses challenges for non-specialist researchers and therapy developers in effectively studying these biomolecules. Analytical procedures are further complicated by multi-step protocols and demanding expertise, often resulting in sample contamination and inconsistent test results. Recent advancements in approaches, such as utilizing complementary techniques and the middle-up strategy for analyzing data from diverse bioanalytical techniques in glycan profiling and analysis, necessitate considerable domain expertise. Consequently, drug developers and medical researchers increasingly rely on contract service providers equipped with the necessary analytical expertise and technical infrastructure for glycan analysis. Presently, more than 130 industry and non-industry entities claim to actively provide glycan analysis services. Notably, numerous stakeholders in the service sector have formed strategic alliances or acquired other players offering glycan analysis services for monoclonal antibodies or related services, intending to expand their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to enhance and broaden their offerings, steady growth is expected in the contract services market for glycan analysis during the forecast period.
Report Coverage
Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as a swiftly expanding class of pharmacologically active compounds. Currently, over 67% of biologics and 80% of FDA-approved biosimilars incorporate some form of glycosylation. Notably, the pipeline for these interventions is experiencing substantial growth at a Compound Annual Growth Rate (CAGR) exceeding 20%. It's crucial to underscore that in higher eukaryotes like humans, DNA glycosylation of specific biomolecules holds not only functional significance but also provides beneficial pharmacological properties, impacting efficacy, solubility, stability, and antigen binding. Additionally, glycans serve as promising biomarkers aiding in disease prognosis, diagnosis, and predicting treatment efficacy. Various abnormal glycan molecules associated with tumors (e.g., Tn, sialyl-T, sialyl-Tn) and virulent glycoproteins on pathogenic viral surfaces (like the glycan shield linked to the SARS-CoV-2 spike glycoprotein) are presently being investigated as potential therapeutic targets.
However, the complex nature of glycan analysis poses challenges for non-specialist researchers and therapy developers in effectively studying these biomolecules. Analytical procedures are further complicated by multi-step protocols and demanding expertise, often resulting in sample contamination and inconsistent test results. Recent advancements in approaches, such as utilizing complementary techniques and the middle-up strategy for analyzing data from diverse bioanalytical techniques in glycan profiling and analysis, necessitate considerable domain expertise. Consequently, drug developers and medical researchers increasingly rely on contract service providers equipped with the necessary analytical expertise and technical infrastructure for glycan analysis. Presently, more than 130 industry and non-industry entities claim to actively provide glycan analysis services. Notably, numerous stakeholders in the service sector have formed strategic alliances or acquired other players offering glycan analysis services for monoclonal antibodies or related services, intending to expand their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to enhance and broaden their offerings, steady growth is expected in the contract services market for glycan analysis during the forecast period.
Report Coverage
- The report examines the glycan analysis market, focusing on factors such as company size, analytical techniques, and geographical considerations.
- Analysis encompasses market growth influencers like drivers, restraints, opportunities, and challenges.
- Assessments outline the market's advantages, obstacles, and competitive landscape for leading players.
- Revenue forecasts for market segments across various countries are provided.
- Evaluation of industry players in glycan analysis services includes criteria such as establishment year, company size, headquarters location, and offered services, covering glycan profiling, structure analysis, glycosylation site mapping, among others. It also reviews additional services such as peptide mapping, glycan synthesis, and availability of synthetic glycans and analytical kits. Non-industry players' glycoanalytical services and techniques are examined.
- Region-specific evaluations highlight notable glycan analysis service providers based on supplier strength (experience, company size) and portfolio specifics (services offered, analytical techniques, glycans analyzed, analytes processed, and applications).
- Detailed profiles of key glycan analysis service providers include company overview, service portfolio, recent developments, and future outlook.
- Assessment of surface glycan targeting therapeutics includes their status in commercial, clinical, preclinical, and discovery phases, covering lead candidates, target diseases, drug molecules, therapy types, technology platforms, and developer details.
- Analysis of grants awarded to research institutes for surface glycan targeting therapeutic projects between 2016 and 2021, considering grant details, administering institutes, recipient organizations, geographical distribution, funding centers, program officers, and focus areas.
- Examination of partnerships involving acquisitions, mergers, licensing agreements, product and research developments in the glycan analysis market since 2015.
- Analysis of mergers and acquisitions between 2015 and 2021, considering deal types, company size, headquarters' locations, and key value drivers, including an ownership change matrix highlighting private and public sector involvement.
- A case study on Fc glycoengineered antibody developers, covering establishment year, company size, headquarters location, development phase, disease indication, therapeutic area, molecule type, biological target, therapy type, route of administration, Fc engineering impact, and technology platform. These structured points constitute a comprehensive analysis framework for the glycan analysis market and surface glycan targeting therapeutics.
- CD BioGlyco
- Creative Biolabs
- Creative Proteomics
- Thermo Fisher Scientific
- Glykos Finland
- glyXera
- Ludger
- Protagen Protein Services
- Mithra Biotechnology
- Protein Works
- Savyon Diagnostics
- Syngene
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Glycans and Glycoconjugates
3.3. Glycosylation of Therapeutic Proteins
3.4. Overview of Protein Glycosylation Analysis (Glycan Analysis)
3.4.1. Methods Used in Glycan Analysis
3.4.2. Techniques Used for Glycan Analysis
3.5. Outsourcing Glycan Analysis
3.5.1. Need for Outsourcing
3.5.2. Advantages of Outsourcing
3.5.3. Guidelines for Selecting a Service Provider
3.6. Concluding Remarks
4. GLYCAN ANALYSIS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Glycan Analysis Service Providers: Overall Market Landscape
4.2.1. Glycan Analysis Service Providers: Industry Players
4.2.1.1. Analysis by Year of Establishment
4.2.1.2. Analysis by Company Size
4.2.1.3. Analysis by Location of Headquarters
4.2.1.4. Analysis by Availability of Contract Development and Manufacturing Capabilities
4.2.1.5. Analysis by Type of Service Offered
4.2.1.6. Analysis by Type of Glycoconjugate / Glycan Analyzed
4.2.1.7. Analysis by Type of Sample Processed
4.2.1.8. Analysis by Type of Analyte Processed
4.2.1.9. Analysis by Type of Analytical Technique Used
4.2.1.10. Analysis by Application Area
4.2.1.11. Analysis by Additional Services Offered
4.2.1.12. Analysis by Additional Products Offered
4.2.2. Glycan Analysis Service Providers: Non-Industry Players
4.2.2.1. Analysis by Service Location
4.2.2.2. Analysis by Type of Service Offered
4.2.2.3. Analysis by Type of Analytical Technique Used
5. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.3.1. Competitiveness Analysis: Glycan Analysis Service Providers in North America
5.3.2. Competitiveness Analysis: Glycan Analysis Service Providers in Europe
5.3.3. Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
5.4. Summary of Key Players
6. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Glycan Analysis Service Providers: North America
6.2.1. CD BioGlyco
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook
6.2.3. Creative Proteomics
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Thermo Fisher Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.3. Glycan Analysis Service Providers: Europe
6.3.1. Glykos Finland
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. glyXera
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Ludger
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Protagen Protein Services
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook
6.4. Glycan Analysis Service Providers: Asia-Pacific and rest of the world
6.4.1. Mithra Biotechnology
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Protein Works
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. Savyon Diagnostics
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Syngene
6.4.4.1. Company Overview
6.4.4.2. Financial Information
6.4.4.3. Service Portfolio
6.4.4.4. Recent Developments and Future Outlook
7. SURFACE GLYCAN TARGETING THERAPEUTICS: OVERALL MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Surface Glycan Targeting Therapeutics: Pipeline Review
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Target Disease Indication and Therapeutic Area
7.2.3. Analysis by Type of Drug Molecule
7.2.4. Analysis by Phase of Development and Therapeutic Area
7.2.5. Analysis by Type of Drug Molecule and Therapeutic Area
7.2.6. Analysis by Target Glycoconjugate and Glycan Molecule
7.2.7. Analysis by Type of Therapy
7.2.8. Popular Technology Platforms: Distribution by Number of Products
7.3. Surface Glycan Targeting Therapeutics: List of Developers
7.3.1. Analysis by Type of Player
7.3.2. Analysis by Year of Establishment
7.3.3. Analysis by Company Size
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Players: Analysis by Number of Products
7.4. Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Product’s Stage of Development
8. SURFACE GLYCAN TARGETING THERAPEUTICS: ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Surface Glycan Targeting Therapeutics: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Word Cloud Analysis: Emerging Focus Areas
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partner
9.3.4. Analysis by Type of Partnership and Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Parent Company
9.3.6. Analysis by Type of Partnership and Type of Parent Company
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.9. Intercontinental and Intracontinental Agreements
9.3.10. Analysis by Therapeutic Area
10. MERGERS AND ACQUISITONS
10.1. Chapter Overview
10.2. Merger and Acquisition Models
10.3. List of Mergers and Acquisitions
10.3.1. Analysis by Type of Deal
10.3.2. Analysis by Year of Deal
10.3.3. Analysis by Geography
10.3.4. Intercontinental and Intracontinental Deals
10.3.5. Analysis by Company Size
10.3.6. Ownership Change Matrix
10.3.7. Key Players: Analysis by Number of Mergers and Acquisitions
10.3.8. Analysis by Key Value Drivers
11. CASE STUDY ON POTENTIAL CLIENTS OF GLYCAN ANALYSIS SERVICE PROVIDERS
11.1. Chapter Overview
11.2. List of Fc Glycoengineered Antibody Developers
11.2.1. Analysis by Year of Establishment
11.2.2. Analysis by Company Size
11.2.3. Analysis by Location of Headquarters
11.2.4. Leading Players: Analysis by Number of Products
11.3. Fc Glycoengineered Antibody Therapeutics: Pipeline Review
11.3.1. Analysis by Phase of Development
11.3.2. Analysis by Target Disease Indication
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Antibody
11.3.5. Analysis by Type of Biological Target
11.3.6. Analysis by Type of Therapy
11.3.7. Analysis by Route of Administration
11.3.8. Analysis by Impact of Fc Engineering
11.3.9. Analysis by Technology Platform Used
12. GLYCAN ANALYSIS SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Glycan Analysis Services Market, 2021-2030
12.4. Global Glycan Analysis Services Market, 2021-2030: Distribution by Company Size
12.4.1. Glycan Analysis Services Market for Small Companies, 2021-2030
12.4.2. Glycan Analysis Services Market for Mid-sized Companies, 2021-2030
12.4.3. Glycan Analysis Services Market for Large Companies, 2021-2030
12.5. Global Glycan Analysis Services Market, Distribution by Type of Analytical Technique, 2021-2030
12.5.1. Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030
12.5.2. Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030
12.5.3. Glycan Analysis Services Market for Microarray-based Techniques, 2021-2030
12.5.4. Glycan Analysis Services Market for Electrophoresis-based Techniques, 2021-2030
12.6. Global Glycan Analysis Services Market, 2021-2030: Distribution by Geography
12.6.1 Glycan Analysis Services Market in the US, 2021-2030
12.6.2 Glycan Analysis Services Market in Canada, 2021-2030
12.6.3 Glycan Analysis Services Market in the UK, 2021-2030
12.6.4 Glycan Analysis Services Market in France, 2021-2030
12.6.5 Glycan Analysis Services Market in Germany, 2021-2030
12.6.6 Glycan Analysis Services Market in Spain, 2021-2030
12.6.7 Glycan Analysis Services Market in Italy, 2021-2030
12.6.8 Glycan Analysis Services Market in Rest of Europe, 2021-2030
12.6.9 Glycan Analysis Services Market in China, 2021-2030
12.6.10 Glycan Analysis Services Market in Japan, 2021-2030
12.6.11 Glycan Analysis Services Market in India, 2021-2030
12.6.12 Glycan Analysis Services Market in Asia-Pacific and rest of the world, 2021-2030
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. GlycoAnalytics Core, University of California
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Biswa Choudhury, Technical Director
13.2. glyXera
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Erdmann Rapp, Founder and Chief Executive Officer
13.3. Glykos Finland
13.3.1. Company / Organization Overview
13.3.2. Interview Transcript: Juhani Saarinen, Chief Executive Officer
14. CONCLUDING REMARKS
14.1. Chapter Overview
15. APPENDIX 1: TABULATED DATA
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Glycans and Glycoconjugates
3.3. Glycosylation of Therapeutic Proteins
3.4. Overview of Protein Glycosylation Analysis (Glycan Analysis)
3.4.1. Methods Used in Glycan Analysis
3.4.2. Techniques Used for Glycan Analysis
3.5. Outsourcing Glycan Analysis
3.5.1. Need for Outsourcing
3.5.2. Advantages of Outsourcing
3.5.3. Guidelines for Selecting a Service Provider
3.6. Concluding Remarks
4. GLYCAN ANALYSIS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Glycan Analysis Service Providers: Overall Market Landscape
4.2.1. Glycan Analysis Service Providers: Industry Players
4.2.1.1. Analysis by Year of Establishment
4.2.1.2. Analysis by Company Size
4.2.1.3. Analysis by Location of Headquarters
4.2.1.4. Analysis by Availability of Contract Development and Manufacturing Capabilities
4.2.1.5. Analysis by Type of Service Offered
4.2.1.6. Analysis by Type of Glycoconjugate / Glycan Analyzed
4.2.1.7. Analysis by Type of Sample Processed
4.2.1.8. Analysis by Type of Analyte Processed
4.2.1.9. Analysis by Type of Analytical Technique Used
4.2.1.10. Analysis by Application Area
4.2.1.11. Analysis by Additional Services Offered
4.2.1.12. Analysis by Additional Products Offered
4.2.2. Glycan Analysis Service Providers: Non-Industry Players
4.2.2.1. Analysis by Service Location
4.2.2.2. Analysis by Type of Service Offered
4.2.2.3. Analysis by Type of Analytical Technique Used
5. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.3.1. Competitiveness Analysis: Glycan Analysis Service Providers in North America
5.3.2. Competitiveness Analysis: Glycan Analysis Service Providers in Europe
5.3.3. Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
5.4. Summary of Key Players
6. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Glycan Analysis Service Providers: North America
6.2.1. CD BioGlyco
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook
6.2.3. Creative Proteomics
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Thermo Fisher Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.3. Glycan Analysis Service Providers: Europe
6.3.1. Glykos Finland
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. glyXera
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Ludger
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Protagen Protein Services
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook
6.4. Glycan Analysis Service Providers: Asia-Pacific and rest of the world
6.4.1. Mithra Biotechnology
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Protein Works
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. Savyon Diagnostics
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Syngene
6.4.4.1. Company Overview
6.4.4.2. Financial Information
6.4.4.3. Service Portfolio
6.4.4.4. Recent Developments and Future Outlook
7. SURFACE GLYCAN TARGETING THERAPEUTICS: OVERALL MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Surface Glycan Targeting Therapeutics: Pipeline Review
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Target Disease Indication and Therapeutic Area
7.2.3. Analysis by Type of Drug Molecule
7.2.4. Analysis by Phase of Development and Therapeutic Area
7.2.5. Analysis by Type of Drug Molecule and Therapeutic Area
7.2.6. Analysis by Target Glycoconjugate and Glycan Molecule
7.2.7. Analysis by Type of Therapy
7.2.8. Popular Technology Platforms: Distribution by Number of Products
7.3. Surface Glycan Targeting Therapeutics: List of Developers
7.3.1. Analysis by Type of Player
7.3.2. Analysis by Year of Establishment
7.3.3. Analysis by Company Size
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Players: Analysis by Number of Products
7.4. Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Product’s Stage of Development
8. SURFACE GLYCAN TARGETING THERAPEUTICS: ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Surface Glycan Targeting Therapeutics: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Word Cloud Analysis: Emerging Focus Areas
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partner
9.3.4. Analysis by Type of Partnership and Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Parent Company
9.3.6. Analysis by Type of Partnership and Type of Parent Company
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.9. Intercontinental and Intracontinental Agreements
9.3.10. Analysis by Therapeutic Area
10. MERGERS AND ACQUISITONS
10.1. Chapter Overview
10.2. Merger and Acquisition Models
10.3. List of Mergers and Acquisitions
10.3.1. Analysis by Type of Deal
10.3.2. Analysis by Year of Deal
10.3.3. Analysis by Geography
10.3.4. Intercontinental and Intracontinental Deals
10.3.5. Analysis by Company Size
10.3.6. Ownership Change Matrix
10.3.7. Key Players: Analysis by Number of Mergers and Acquisitions
10.3.8. Analysis by Key Value Drivers
11. CASE STUDY ON POTENTIAL CLIENTS OF GLYCAN ANALYSIS SERVICE PROVIDERS
11.1. Chapter Overview
11.2. List of Fc Glycoengineered Antibody Developers
11.2.1. Analysis by Year of Establishment
11.2.2. Analysis by Company Size
11.2.3. Analysis by Location of Headquarters
11.2.4. Leading Players: Analysis by Number of Products
11.3. Fc Glycoengineered Antibody Therapeutics: Pipeline Review
11.3.1. Analysis by Phase of Development
11.3.2. Analysis by Target Disease Indication
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Antibody
11.3.5. Analysis by Type of Biological Target
11.3.6. Analysis by Type of Therapy
11.3.7. Analysis by Route of Administration
11.3.8. Analysis by Impact of Fc Engineering
11.3.9. Analysis by Technology Platform Used
12. GLYCAN ANALYSIS SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Glycan Analysis Services Market, 2021-2030
12.4. Global Glycan Analysis Services Market, 2021-2030: Distribution by Company Size
12.4.1. Glycan Analysis Services Market for Small Companies, 2021-2030
12.4.2. Glycan Analysis Services Market for Mid-sized Companies, 2021-2030
12.4.3. Glycan Analysis Services Market for Large Companies, 2021-2030
12.5. Global Glycan Analysis Services Market, Distribution by Type of Analytical Technique, 2021-2030
12.5.1. Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030
12.5.2. Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030
12.5.3. Glycan Analysis Services Market for Microarray-based Techniques, 2021-2030
12.5.4. Glycan Analysis Services Market for Electrophoresis-based Techniques, 2021-2030
12.6. Global Glycan Analysis Services Market, 2021-2030: Distribution by Geography
12.6.1 Glycan Analysis Services Market in the US, 2021-2030
12.6.2 Glycan Analysis Services Market in Canada, 2021-2030
12.6.3 Glycan Analysis Services Market in the UK, 2021-2030
12.6.4 Glycan Analysis Services Market in France, 2021-2030
12.6.5 Glycan Analysis Services Market in Germany, 2021-2030
12.6.6 Glycan Analysis Services Market in Spain, 2021-2030
12.6.7 Glycan Analysis Services Market in Italy, 2021-2030
12.6.8 Glycan Analysis Services Market in Rest of Europe, 2021-2030
12.6.9 Glycan Analysis Services Market in China, 2021-2030
12.6.10 Glycan Analysis Services Market in Japan, 2021-2030
12.6.11 Glycan Analysis Services Market in India, 2021-2030
12.6.12 Glycan Analysis Services Market in Asia-Pacific and rest of the world, 2021-2030
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. GlycoAnalytics Core, University of California
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Biswa Choudhury, Technical Director
13.2. glyXera
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Erdmann Rapp, Founder and Chief Executive Officer
13.3. Glykos Finland
13.3.1. Company / Organization Overview
13.3.2. Interview Transcript: Juhani Saarinen, Chief Executive Officer
14. CONCLUDING REMARKS
14.1. Chapter Overview
15. APPENDIX 1: TABULATED DATA
